1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)" is currently closed and not accepting applications.
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH).
This Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program.
It specifically focuses on applications directed at improving pain measurement and treatment, including the discovery and pre-clinical development of non-addictive pain analgesic treatments with little or no addiction liability, such as small molecules.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
RFA-NS-23-006 - HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is used for the submission of applications to the following Notices of Special Interest (NOSIs) | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health RFA-NS-23-006 - HEAL INITIATIVE: Development of Therapies and Technologies Directed at
Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is used for the submission of applications to the following Notices of Special Interest (NOSIs) Notice of Change to correct ORIPs listing under Components of Participating Organizations for PA-23-080, PA-23-230, PA-23-232, PAR-23-138, RFA-NS-23-006, and RFA-NS-23-007 R41/R42, R43/R44, S10, T35 Notice of NHLBI Specific Interests and Guidance in RFA-NS-23-006 "HEAL INITIATIVE: Development of
Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)" For technical issues E-mail OER Webmaster
According to the current listing, eligibility includes: Small businesses. Confirm the full requirements in the official notice before applying.
The current listing shows not specified (SBIR Phase I and II generally up to $306,872 for Phase I and $2,045,816 for Phase II). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was April 4, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article